GNFT

GENFIT

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$253.6M

Burn Rate (Qtr)

$75.3M

Company Profile

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Elafibranor

Primary Biliary Cholangitis

Phase 3 (Data)

TBD

Nitazoxanide

NASH-induced significant or severe fibrosis

Phase 2

TBD

TGFTX1

Psoriasis or Respiratory Conditions

Pre-Clinical

TBD

Elafibranor

Non-alcoholic steatohepatitis (NASH)

Discontinued

Discontinued

Recent Posts

See what the community is saying - click to see full post

GNFT - GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

Do prior negative Seladalpar results translate to GNFT's upcoming Elafibranor NASH readout?

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon